11494 Sorrento Valley Road
425 articles with Inovio
Inovio Pharmaceuticals, Inc. announced the pricing of its offering of $65.0 million aggregate principal amount of 6.50% convertible senior notes due 2024.
First Human dMAb Study Will Target Zika Infection
Companies Continue to Take Aim at Glioblastoma, a Cancer Highlighted by the Death of Sen. John Mc...
8/27/2018McCain died Saturday after deciding to discontinue treatment for brain cancer. He approached the end of his life in the same manner in which he approached me that day in Raleigh – with the strength of character.
In the biotech world, only 7 to 9 percent of companies have women as their chief executives. Antiva BioSciences is a good example of how this problem is perpetuated.
8/15/2018On a dollar-for-dollar basis, vaccines have probably had a greater positive effect on global health than any other medical advancement, except possibly antibiotics. Yet as a whole, it’s an area that pharma companies tend to not spend a lot of resources on. But there are still many companies that ...
Ebola cases, as well as cases of other significantly lethal viral outbreaks that have occurred has spurred researchers to focus on the development of antivirals that can treat the illnesses.
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
The 2017/2018 influenza season was considered one of the worst, made more so by the ineffectiveness of the season’s flu vaccine. The FDA is focusing partially on simply determining why this year’s flu vaccine missed the mark.
Inovio and The Wistar Institute Receive More Than $4.6M in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria
The grants were from the Bill & Melinda Gates Foundation and the (NIH.
Inovio Pharmaceuticals' Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major, Lethal H1N1 Influenza Viruses From the Last 100 Years in Animal Models
The flu vaccine also affords 100% protection against lethal challenge in the gold standard ferret model, demonstrating the functionality of such broad protective immune responses.
Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations
The initial trial under consideration between Inovio and the Parker Institute would address muscle invasive bladder cancer with INO-5401 in combination with checkpoint inhibitors and immune modulators.
Inovio Receives Milestone Payment From MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase II
First efficacy trial to evaluate Inovio’s cancer immunotherapy targeting HPV in combination with durvalumab.
Based on the new agreement, ApolloBio will make an upfront payment of $23M, as well as potential future payments up to $20M upon meeting certain milestones.
New strategic position will guide product discovery anDr. Humeau will serve an integral role in advancing Inovio's portfolio of ASPIRE immunotherapies and vaccinesd scientific collaborations.
Wendy Yarno has over 25 years of experience in the pharmaceutical industry highlighted by her tenure at Merck where she served as chief marketing officer.
Inovio’s Further Analysis of VGX-3100 Phase IIb Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy
Inovio continues to investigate pre-treatment biomarkers which could identify patients most likely to respond to treatment with VGX-3100, increasing absolute efficacy of the product.
Inovio Pharmaceuticals SynCon TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model
The combination therapies resulted in robust anti-tumor effects and showed significant improvement in survival compared to either therapy alone.
Total revenue was $2.6 million for the three months ended September 30, 2017, compared to $12.5 million for the same period in 2016.
Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron's PD-1 Inhibitor
Phase 1b/2a clinical trial combines Regeneron’s PD-1 inhibitor cemiplimab and Inovio’s T cell activator INO-5401 in brain cancer.
A live and archived version of the audio presentation will be available online.